Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)

BACKGROUND: Real-world data on extended follow-up of patients with BRAF V600-mutant metastatic melanoma are limited. We investigated dabrafenib plus trametinib (dab + tram) outside of a clinical trial setting (Individual Patient Program; DESCRIBE Italy). OBJECTIVE: To describe the baseline features,...

Descripción completa

Detalles Bibliográficos
Autores principales: Aglietta, Massimo, Chiarion-Sileni, Vanna, Fava, Paolo, Guidoboni, Massimo, Depenni, Roberta, Minisini, Alessandro, Consoli, Francesca, Ascierto, Paolo, Rinaldi, Gaetana, Banzi, Maria, Marconcini, Riccardo, Gueli, Rossana, Ferraresi, Virginia, Tucci, Marco, Tonini, Giuseppe, Lo Re, Giovanni, Guida, Michele, Del Vecchio, Michele, Marcon, Ilaria Gioia, Queirolo, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613139/
https://www.ncbi.nlm.nih.gov/pubmed/34755244
http://dx.doi.org/10.1007/s11523-021-00850-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613139/
https://www.ncbi.nlm.nih.gov/pubmed/34755244
http://dx.doi.org/10.1007/s11523-021-00850-1

Ejemplares similares